Nikolaos Charalampakis

Dr. Nikolaos Charalampakis

Metaxa Cancer Hospital
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
Christo KOLEChristo KOLE
Christo KOLE
PEPanagiota Economopoulou
Panagiota Economopoulou
EKEvangelos Koustas
Evangelos Koustas
MKMichalis V. Karamouzis
Michalis V. Karamouzis

8 May 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
KTKONSTANTINOS TSAMAKIS
KONSTANTINOS TSAMAKIS
MGMaria Gavriatopoulou
Maria Gavriatopoulou
DSDimitrios Schizas
Dimitrios Schizas
ASAthina Stravodimou
Athina Stravodimou
AMAikaterini Mougkou
Aikaterini Mougkou
EREmmanouil Rizos
Emmanouil Rizos
COVID‑19 has caused unprecedented societal turmoil, triggering a rapid, still ongoing, transformation of healthcare provision on a global level. In this new landscape, it is highly important to acknowledge the challenges this pandemic poses on the care of the particularly vulnerable cancer patients and the subsequent psychosocial impact on them. We have outlined our clinical experience in managing patients with gastrointestinal, hematological, gynaecological, dermatological, neurological, thyroid, lung and paediatric cancers in the COVID‑19 era and have reviewed the emerging literature around barriers to care of oncology patients and how this crisis affects them. Moreover, evolving treatment strategies and novel ways of addressing the needs of oncology patients in the new context of the pandemic are discussed.

13 December 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
PEPanagiota Economopoulou
Panagiota Economopoulou
IKIoannis Kotsantis
Ioannis Kotsantis
MTMaria Tolia
Maria Tolia
DSDimitrios Schizas
Dimitrios Schizas
APAmanda Psyrri
Amanda Psyrri
Gastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A multimodality approach to therapy is the cornerstone of screening, diagnosing, staging, treating and supporting patients with gastric cancer. The evidence‐based approach to localized gastric cancer (>cT1b) is to use an either preoperative or postoperative strategy to maximize the benefit of surgery. The focus of future research is to optimize chemotherapy regimens, determine the role of radiation therapy and investigate the effect of treatment timing. In metastatic gastric cancer, biologic therapies have been introduced targeting markers shown to be prognostic. The results of ongoing randomized controlled phase 3 trials using targeted and immunotherapy agents, either in combination or alone, have the potential to alter the current treatment landscape of advanced gastric cancer.

4 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Christo KOLEChristo KOLE
Christo KOLE
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
STSergios Tsakatikas
Sergios Tsakatikas
MVMichail Vailas
Michail Vailas
Dimitrios MorisDimitrios Moris
Dimitrios Moris
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
Hepatocellular carcinoma (HCC) is one of one of the most frequent liver cancers and the fourth leading cause of cancer-related mortality worldwide. Current treatment options such as surgery, neoadjuvant chemoradiotherapy, liver transplantation, and radiofrequency ablation will benefit only a very small percentage of patients. Immunotherapy is a novel treatment approach representing an effective and promising option against several types of cancer. The aim of our study is to present the currently ongoing clinical trials and to evaluate the efficacy of immunotherapy in HCC. In this paper, we demonstrate that combination of different immunotherapies or immunotherapy with other modalities results in better overall survival (OS) and progression-free survival (PFS) compared to single immunotherapy agent. Another objective of this paper is to demonstrate and highlight the importance of tumor microenvironment as a predictive and prognostic marker and its clinical implications in immunotherapy response.

6 April 2016 in Oncology
Verified
Journal Article
Open access
PDF file
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
GNGraciela Nogueras
Graciela Nogueras
EEElena Elimova
Elena Elimova
RWRoopma Wadhwa
Roopma Wadhwa
HSHironori Shiozaki
Hironori Shiozaki
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Background: Patients with localized gastric adenocarcinoma (LGAC), who get pre-operative therapy, have heterogeneous/unpredictable outcomes. Predictive clinical variables/biomarkers are not established. Methods: We analyzed 107 LGAC patients who had chemoradiation and surgery. LGACs were grouped for (1) presence/absence of signet ring cell histology (SRC) and (2) histologic grade: G2 or G3. %SRC was assessed (0, 1-10, 11-49, and 50-100%) and correlated with pathologic complete response (pathCR) or <pathCR in the resected specimens. Results: Most patients were men (60%), had stage cIII LGAC (50%), and received chemotherapy before chemoradiation (93%). Most had G3 tumors (78%) and SRC (58%). Presence of SRC was associated with a lower rate of pathCR (11 vs. 36%, p = 0.004), and the association remained significant even with a low percentage of SRC (1-10%; p = 0.014). The higher the fraction of SRC, the lower was the probability of pathCR (p = 0.03). G3 and SRC led to a shorter overall survival (OS) (p = 0.046 and p = 0.038, respectively). yp stage independently prognosticated OS and recurrence-free survival (p < 0.001). Conclusion: Our novel findings suggest that LGACs with SRC are relatively chemoradiation resistant compared to LGACs without SRC. A higher fraction of SRC is associated with higher resistance. Upon validation/biomarker(s) evaluation, reporting of the fraction of SRC may be warranted.

1 November 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
EEElena Elimova
Elena Elimova
XWXuemei Wang
Xuemei Wang
EEElba Etchebehere
Elba Etchebehere
HSHironori Shiozaki
Hironori Shiozaki
YSYusuke Shimodaira
Yusuke Shimodaira
Jaffer AjaniJaffer Ajani
Jaffer Ajani